Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belém, Brazil.
暂无分享,去创建一个
A. Linhares | R. B. Freitas | Y. Gabbay | J. D. Mascarenhas | A C Linhares | Y B Gabbay | J D Mascarenhas | R B de Freitas | C S Oliveira | N Bellesi | T A Monteiro | Z Lins-Lainson | F L Ramos | S A Valente | N. Bellesi | S. A. Valente | R. B. de Freitas | F. L. Ramos | T. Monteiro | C. S. Oliveira | Z. Lins-Lainson | F. Ramos | J. Mascarenhas | T. A. Monteiro
[1] M. Vilar,et al. Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants , 1989, Journal of clinical microbiology.
[2] R. Black,et al. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. , 1996, Vaccine.
[3] D. Bernstein,et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. , 1989, The Journal of infectious diseases.
[4] R. Black,et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. , 1989, The Journal of infectious diseases.
[5] D. Bernstein,et al. Local and systemic antibody response to rotavirus WC3 vaccine in adult volunteers. , 1989, Antiviral research.
[6] M. Pichichero,et al. A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants. , 1993, Vaccine.
[7] Theodore A. Mork,et al. Young Children , 1949, Nature.
[8] R. Chanock,et al. Reassortant rotaviruses as potential live rotavirus vaccine candidates , 1985, Journal of virology.
[9] D. Bruckner,et al. Techniques for the recovery and identification of Cryptosporidium oocysts from stool specimens , 1983, Journal of clinical microbiology.
[10] H. Greenberg,et al. Direct serotyping of human rotavirus in stools by an enzyme-linked immunosorbent assay using serotype 1-, 2-, 3-, and 4-specific monoclonal antibodies to VP7. , 1987, The Journal of infectious diseases.
[11] R. Glass,et al. Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children , 1995 .
[12] G. Gerna,et al. Characterization of serotypes of human rotavirus strains by solid-phase immune electron microscopy. , 1985, The Journal of infectious diseases.
[13] T. Vesikari,et al. Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates. , 1992, The Pediatric infectious disease journal.
[14] A. Kapikian,et al. PROTECTION AGAINST SEVERE ROTAVIRUS DIARRHOEA BY RHESUS ROTAVIRUS VACCINE IN VENEZUELAN INFANTS , 1987, The Lancet.
[15] M. Pichichero,et al. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups. , 1992, The Journal of infectious diseases.
[16] Y. Hoshino,et al. Single GeneSubstitution Rotavirus Reassortants Containing the MajorNeutralization Protein (VP7)ofHumanRotavirus Serotype 4 , 1986 .
[17] M. Levine,et al. Use of DNA probes and HEp-2 cell adherence assay to detect diarrheagenic Escherichia coli. , 1988, The Journal of infectious diseases.
[18] G. Barnes,et al. Estimation of rotavirus immunoglobulin G antibodies in human serum samples by enzyme-linked immunosorbent assay: expression of results as units derived from a standard curve , 1984, Journal of clinical microbiology.
[19] P. Offit,et al. Response of mice to rotaviruses of bovine or primate origin assessed by radioimmunoassay, radioimmunoprecipitation, and plaque reduction neutralization , 1983, Infection and immunity.
[20] T. Vesikari,et al. Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity. , 1991, Vaccine.
[21] E. C. Loureiro,et al. Longitudinal study of rotavirus infections among children from Belém, Brazil , 1989, Epidemiology and Infection.
[22] T. Vesikari,et al. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. , 1992, The Pediatric infectious disease journal.
[23] R. Feachem,et al. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. , 1985, Bulletin of the World Health Organization.
[24] R. Glass,et al. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. , 1991, American journal of diseases of children.
[25] R. Bishop. Development of candidate rotavirus vaccines. , 1993, Vaccine.
[26] G. Zissis,et al. PROTECTION OF INFANTS AGAINST ROTAVIRUS DIARRHOEA BY RIT 4237 ATTENUATED BOVINE ROTAVIRUS STRAIN VACCINE , 1984, The Lancet.
[27] A. Kapikian,et al. Evaluation of the antigenicity and reactogenicity of varying formulations of the rhesus rotavirus‐based quadrivalent and the M37 rotavirus vaccine candidates , 1994, Journal of medical virology.
[28] E. C. Loureiro,et al. Acute diarrhoea associated with rotavirus among children living in Belém, Brazil. , 1983, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[29] A. Ghafoor,et al. Comparative evaluation of the WHO and DAKOPATTS enzyme-linked immunoassay kits for rotavirus detection. , 1989, Bulletin of the World Health Organization.
[30] K. Midthun. Reassortant Rotaviruses asPotential LiveRotavirus Vaccine Candidates , 1985 .
[31] R. Chanock,et al. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4 , 1986, Journal of clinical microbiology.